确定肝硬化伴静脉曲张出血患者TIPS术后门腔压力梯度最佳测量时机与血流动力学目标
该前瞻性研究纳入2018年5月至2021年12月466例因复发性静脉曲张出血接受覆膜TIPS的连续患者,在术后即刻、24-72小时和1个月测量门腔压力梯度(PPG)。结果显示24-72小时PPG与长期PPG及临床结局相关,早期PPG 11-14 mmHg与肝性脑病风险降低相关且不损害临床疗效。
要点
- TIPS术后24-72小时测量的PPG与长期PPG和临床结局相关,即刻PPG则无关。
- 早期PPG≥12 mmHg与门静脉高压并发症风险升高相关(调整HR 2.17)。
- 早期PPG 11-14 mmHg与肝性脑病风险降低相关且不损害临床疗效。
核心结论
- TIPS术后24-72小时测量的PPG与长期PPG及临床结局相关,目标PPG 11-14 mmHg与肝性脑病风险降低相关且不损害临床疗效。
研究设计与样本
- 前瞻性纳入2018年5月至2021年12月466例因复发性静脉曲张出血接受覆膜TIPS的连续患者。
- 术后即刻、24-72小时和1个月分别测量PPG,用组内相关系数(ICC)和Bland-Altman法评估不同时间点PPG的一致性。
- 采用Fine and Gray竞争风险回归模型评估PPG对临床结局的未调整和混杂因素调整效应。
主要发现
- 早期PPG与晚期PPG的一致性(ICC 0.34)优于即刻PPG与晚期PPG的一致性(ICC 0.23,p<0.001)。
- 早期PPG≥12 mmHg vs <12 mmHg对门静脉高压并发症有预测价值(调整HR 2.17,95%CI 1.33-3.55,p=0.002)。
- 早期PPG对显性肝性脑病有预测价值(调整HR 0.40,95%CI 0.17-0.91,p=0.030),而即刻PPG无预测价值。
- 晚期PPG对门静脉高压并发症风险有预测价值,但对显性肝性脑病无预测价值。
- 以进一步失代偿风险最低为目标,确定早期PPG 11-14 mmHg为最佳血流动力学目标,与显性肝性脑病风险降低和有效预防门静脉高压并发症相关。
关键数值与推荐
- 早期PPG≥12 mmHg vs <12 mmHg:调整HR 2.17(95%CI 1.33-3.55,p=0.002)用于门静脉高压并发症。
- 早期PPG对显性肝性脑病:调整HR 0.40(95%CI 0.17-0.91,p=0.030)。
- 早期PPG与晚期PPG的ICC为0.34,即刻PPG与晚期PPG的ICC为0.23(p<0.001)。
- 最佳血流动力学目标为早期PPG 11-14 mmHg。
- 目标为术后24-72小时PPG 11-14 mmHg或较术前基线相对降低20%-50%。
临床怎么用
- TIPS术后至少24小时测量PPG应用于指导决策以改善临床结局。
- 作者认为,术后24-72小时PPG 11-14 mmHg或较术前基线相对降低20%-50%的目标可用于指导覆膜TIPS的建立和修正。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The optimal timing of measurement and hemodynamic targets of portacaval pressure gradient (PPG) after transjugular intrahepatic portosystemic shunt (TIPS) placement remain unclear. This study aimed to identify the ideal moment for hemodynamic measurements and the optimal target of PPG in patients undergoing covered TIPS for variceal bleeding. METHODS: Between May 2018 and December 2021, 466 consecutive patients with recurrent variceal bleeding treated with covered TIPS were prospectively included. Post-TIPS PPG was measured immediately (immediate PPG), 24-72 hours (early PPG), and again 1 month (late PPG) after TIPS placement. The agreement among PPGs measured at different time points was assessed by intra-class correlation coefficient (ICC) and Bland-Altman method. The unadjusted and confounder-adjusted effects of PPGs on clinical outcomes (portal hypertensive complications [PHCs], overt hepatic encephalopathy [OHE], further decompensation, and death) were assessed using Fine and Gray competing risk regression models. RESULTS: The agreement between early PPG and late PPG (ICC: 0.34) was better than that between immediate PPG and late PPG (ICC: 0.23, p <0.001). Early PPG revealed an excellent predictive value for PHCs (early PPG≥ vs. <12 mmHg: adjusted hazard ratio 2.17, 95% CI 1.33-3.55, p = 0.002) and OHE (0.40, 95% CI 0.17-0.91, p = 0.030), while immediate PPG did not. Late PPG showed a predictive value for PHC risk but not OHE. By targeting the lowest risk of further decompensation, we identified an optimal hemodynamic target with early PPG ranging from 11 to 14 mmHg that was associated with a decreased risk of OHE and effective prevention of PHCs. CONCLUSIONS: PPG measured 24 to 72 hours after TIPS correlates with long-term PPG and clinical outcomes, and a hemodynamic target PPG of 11-14 mmHg is associated with reduced encephalopathy but not compromised clinical efficacy. IMPACT AND IMPLICATIONS: The optimal timing of measurement and hemodynamic targets of portacaval pressure gradient (PPG) after transjugular intrahepatic portosystemic shunt (TIPS) remain unclear. Here we show that post-TIPS PPG measured at least 24 hours but not immediately after the procedure correlated with long-term PPG and clinical events. Thus, PPG measurements taken at least 24 hours after TIPS should be used to guide decision making in order to improve clinical outcomes. Targeting a post-TIPS PPG of 11-14 mmHg or a 20%-50% relative reduction from pre-TIPS baseline measured 24-72 hours after the procedure was associated with reduced encephalopathy but not compromised clinical efficacy. Thus, these criteria could be used to guide TIPS creation and revision in patients with cirrhosis and variceal bleeding undergoing covered TIPS. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov, ID: NCT03590288.
引用
- Lv Y, Wang Q, Luo B, et al. Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding. J Hepatol. 2024. PMID: 39181214. doi:10.1016/j.jhep.2024.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。